For a 74‑year‑old patient with a prior massive myocardial infarction who is statin‑intolerant, should I initiate evolocumab (Repatha) and what dosing and monitoring are recommended?

Repatha (Evolocumab) for Statin-Intolerant Post-MI Patient

Yes, absolutely initiate evolocumab (Repatha) in this 74-year-old patient with prior massive MI who is statin-intolerant—this is a guideline-recommended, evidence-based intervention that will dramatically reduce cardiovascular risk and mortality.

Why Evolocumab is Essential Here

Your patient represents the highest-risk category for recurrent cardiovascular events. The 2025 ACC/AHA guidelines explicitly identify PCSK9 inhibitors like evolocumab as appropriate therapy for statin-intolerant patients with established atherosclerotic cardiovascular disease 1. The 2024 International Lipid Expert Panel reinforces this, stating that when statins cannot be tolerated, PCSK9 inhibitors should be added to achieve the LDL-C target of <55 mg/dL 2.

The Evidence Base

The FOURIER trial (27,564 patients) demonstrated that evolocumab reduced major adverse cardiovascular events by 15% (HR 0.85) and the composite of CV death/MI/stroke by 20% (HR 0.80) in patients with established cardiovascular disease 3. Critically, this benefit was consistent even in patients with baseline LDL-C in the lowest quartile (median 74 mg/dL), meaning aggressive LDL lowering saves lives regardless of starting point.

For statin-intolerant patients specifically, the OSLER extension studies showed evolocumab was safe and effective for up to 2 years, with 57-59% LDL-C reduction and muscle-related adverse events occurring in only 14% of patients—comparable to standard of care alone 4. The GAUSS-4 trial in statin-intolerant patients showed 40% greater LDL-C reduction versus ezetimibe 5.

Dosing Protocol

Start with either dosing regimen 6:

• 140 mg subcutaneously every 2 weeks, OR
• 420 mg subcutaneously once monthly

Both regimens produce equivalent LDL-C reductions of approximately 55-63% 6. The choice depends on patient preference—some prefer less frequent injections (monthly), others prefer smaller volume per injection (biweekly).

Administration Details

• Inject subcutaneously into abdomen, thigh, or upper arm
• Rotate injection sites with each dose
• Available as prefilled autoinjector (SureClick) or prefilled syringe
• Important: Some presentations contain dry natural rubber (latex derivative) in needle cover—prescribe latex-free version if patient has latex sensitivity 6

Monitoring Strategy

Baseline assessment:

• Obtain LDL-C, non-HDL-C, apolipoprotein B, total cholesterol
• Document baseline lipid panel before first dose

Follow-up timeline:

• Week 4: Check LDL-C (earliest measurable effect) 6
• Week 12: Reassess lipid panel to confirm therapeutic response
• Ongoing: Monitor LDL-C every 4-6 weeks until target achieved, then every 3-6 months 2

Target LDL-C: <55 mg/dL (<1.4 mmol/L) 2

If target not achieved at 12 weeks with monthly dosing, you can increase frequency to 420 mg every 2 weeks (though this is primarily indicated for homozygous familial hypercholesterolemia) 6.

Combination Therapy Considerations

Since your patient is statin-intolerant, consider adding ezetimibe 10 mg daily if not already prescribed. The 2024 ILEP guidelines recommend this stepwise approach 2:

1. First-line: Ezetimibe (if tolerated)
2. Second-line: Add evolocumab if LDL-C remains >55 mg/dL after 4-6 weeks
3. Alternative: Bempedoic acid can be considered, though evolocumab is more potent

The combination of ezetimibe + evolocumab can achieve LDL-C reductions exceeding 70% 6.

Safety Profile

Evolocumab has demonstrated excellent tolerability in statin-intolerant populations 4, 5:

• Muscle symptoms: 14% (similar to placebo/standard care)
• Injection site reactions: 2.1% (most common adverse event)
• No increased risk: New-onset diabetes, neurocognitive dysfunction, or anti-drug antibodies
• No discontinuations due to adverse events in long-term studies

Recent 2026 data from the AMUNDSEN trial showed that even ultra-early evolocumab administration (before PCI in acute MI) achieved 82% of patients reaching LDL-C <55 mg/dL at 12 months with excellent safety 7.

Critical Pitfalls to Avoid

1. Don't delay initiation: The 2024 ILEP guidelines emphasize that post-MI patients should have evolocumab added within 4-6 weeks if LDL-C target not met 2. Your patient is already high-risk—start now.

2. Don't undertitrate: Use full therapeutic doses (140 mg Q2W or 420 mg monthly), not reduced doses.

3. Don't forget patient education: Ensure patient understands self-injection technique. Consider first dose in office to demonstrate.

4. Insurance authorization: Document statin intolerance clearly (≥2 statins attempted, including ≥1 at lowest dose) and prior MI to facilitate approval 1.

5. Don't use evolocumab as monotherapy indefinitely without attempting other agents: While appropriate initially in statin-intolerant patients, periodically reassess tolerance to low-dose statins or alternative agents like bempedoic acid 1.

Expected Outcomes

With evolocumab therapy, expect:

• LDL-C reduction: 55-63% from baseline 6
• Median achieved LDL-C: 26-30 mg/dL in clinical trials 6
• Time to effect: Measurable by week 4, maximal by week 12 6
• Cardiovascular risk reduction: 15-20% reduction in MACE over 2-3 years 3

The FOURIER trial showed that 47% of patients achieved LDL-C <25 mg/dL at 48 weeks, with progressive benefit at lower LDL-C levels—there appears to be no lower threshold where benefit stops 6, 3.